Antibiotic News and Research

RSS

Antibiotics are drugs used to treat infections caused by bacteria and other microorganisms.

FDA grants Cepheid marketing clearance for Xpert SA Nasal Complete molecular test

Cepheid today announced it has received clearance from the U.S. Food & Drug Administration (FDA) to market Xpert® SA Nasal Complete, the first and only molecular test designed for the simultaneous detection and differentiation of both Staphylococcus aureus (SA) and Methicillin-resistant Staphylococcus aureus (MRSA) colonization in less than one hour. The test runs on Cepheid's GeneXpert® System, the world's leading molecular platform for accuracy, speed, and ease-of-use.

8 Jun 2010

Salix submits efficacy supplement for XIFAXAN NDA for Non-C IBS and IBS-related bloating

Salix Pharmaceuticals, Ltd. today announced that the Company has submitted an efficacy supplement to NDA 21-361 for XIFAXAN® (rifaximin) 550 mg tablets for the proposed indication of treatment of non-constipation irritable bowel syndrome (Non-C IBS) and IBS-related bloating.

8 Jun 2010

Acella Pharmaceuticals signs license agreement for marketing rights to generic broad-spectrum antibiotic

Acella Pharmaceuticals has signed a licensing agreement for the U.S. marketing rights to a generic version of an intravenous administered broad-spectrum antibiotic.

8 Jun 2010

Researchers develop biosensors to monitor concentration of c-di-GMP within single living bacteria cells

Some species of bacteria perform an amazing reproductive feat. When the single-celled organism splits in two, the daughter cell - the swarmer - inherits a propeller to swim freely. The mother cell builds a stalk to cling to surfaces.

4 Jun 2010

Lovastatin protects animals against plague

An experimental study has revealed that lovastatin, a drug prescribed for the treatment of hypercholesterolemia, protects animals against the deadly effects of plague. This infectious disease is on the upsurge in parts of the world. These results obtained by scientists at the Unité de Recherche sur les Maladies Infectieuses et Tropicales Emergentes (CNRS/Université Aix-Marseille 2) have been published in the journal PLoS ONE.

4 Jun 2010

Phase 1B clinical study with PMX-60056 meets safety and efficacy endpoints: PolyMedix

PolyMedix, Inc., an emerging biotechnology company focused on developing new therapeutic drugs to treat acute cardiovascular disorders and infectious diseases, has successfully completed a second Phase 1B clinical safety and pilot efficacy study with PMX-60056, a small synthetic molecule designed to reverse heparin and low molecular weight heparin anticoagulants.

3 Jun 2010

Oculus launches Microcyn Negative-Pressure Wound Therapy Solution

Oculus Innovative Sciences, Inc., a commercial medical technology company that designs, produces and markets safe and effective tissue care products based upon the Microcyn® Technology platform, today introduced the Microcyn Negative-Pressure Wound Therapy Solution™ for the U.S. professional healthcare market. Within the pH ranges of 6-7.8 desired for optimum negative-pressure wound therapy, Microcyn is intended for the irrigation and management of wounds via these advanced systems.

2 Jun 2010

Santarus commences enrollment in rifamycin SV MMX Phase III clinical program for travelers' diarrhea

Santarus, Inc., a specialty biopharmaceutical company, today announced that is has begun to enroll patients in the first study in its Phase III clinical program to evaluate the efficacy and safety of rifamycin SV MMX® for the treatment of patients with travelers' diarrhea.

2 Jun 2010

Azithromycin as effective as penicillin for early-stage syphilis: Study

In a clinical trial involving HIV-negative volunteers with early-stage syphilis, researchers have found that antibiotic pills (azithromycin) are as effective as penicillin injections in curing early-stage syphilis. The study was supported by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health.

2 Jun 2010

Tetraphase Pharmaceuticals raises $45M in Series C financing

Tetraphase Pharmaceuticals, a clinical stage biopharmaceutical company utilizing breakthrough synthetic chemistry technology to discover and develop next-generation antibiotics, today announced that it has raised $45 million in a Series C financing.

2 Jun 2010

AAPA recognizes role of PAs in transforming health care delivery with 2010 PAragon Awards

The American Academy of Physician Assistants celebrated the role of physician assistants in transforming health care delivery at its 38th Annual Physician Assistant Conference in Atlanta yesterday with its presentation of the 2010 PAragon Awards.

1 Jun 2010

Helicobacter pylori's helical shape helps it colonize the stomach

The bacterium Helicobacter pylori, which lives in the human stomach and is associated with ulcers and gastric cancer, is shaped like a corkscrew, or helix. For years researchers have hypothesized that the bacterium's twisty shape is what enables it to survive - and thrive - within the stomach's acid-drenched environment, but until now they have had no proof.

28 May 2010

Advanced Life Sciences expands partnership with U.S. Government to assess Restanza against STI's

Advanced Life Sciences Holdings, Inc., a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, oncology and respiratory diseases, today announced the expansion of its collaboration with the U.S. Government to include the evaluation of Restanza's activity against sexually transmitted infections (STI's), such as gonorrhea.

28 May 2010

Researchers see plectasin as promising lead compound for new antibiotics

An active compound from fungi and lower animals may well be suitable as an effective weapon against dangerous bacteria. We're talking about plectasin, a small protein molecule that can even destroy highly resistant bacteria . Researchers at the Universities of Bonn, Utrecht, Aalborg and of the Danish company Novozymes AS have shed light on how the substance does this.

28 May 2010

CrystalGenomics to merge with BexPharm

CrystalGenomics, Inc., a leading biopharmaceutical company developing novel small molecule therapeutics announced today that it will merge with BexPharm, a specialty pharmaceutical company that imports and distributes foreign market approved drugs in Korea.

28 May 2010

Progenics presents preclinical data on novel monoclonal antibodies against toxins produced by C. difficile

Progenics Pharmaceuticals, Inc. today announced the presentation of preclinical data on novel monoclonal antibodies against toxins produced by the bacterium Clostridium difficile (C. difficile). The monoclonal antibodies effectively neutralized the cell-killing activities of the toxins in vitro and significantly improved survival in a stringent animal model of C. difficile infection. C. difficile is the leading cause of hospital-acquired diarrhea in the United States and represents a growing global public health challenge.

28 May 2010

National Science Foundation supports PolyMedix with $150,000 grant for development of antimicrobial sutures

PolyMedix, Inc., an emerging biotechnology company focused on developing new therapeutic drugs to treat serious acute cardiovascular disorders and infectious diseases, has received a grant in the amount of $150,000 from the National Science Foundation to support the development of antimicrobial sutures. PolyMedix has developed a series of novel antimicrobial polymers for device and material applications, which it collectively calls the PolyCides™.

27 May 2010

Bacteria may play wider role in people predisposed to obesity: Researchers

Bacteria may play more of a role in people predisposed to obesity than previously thought, according to studies presented today by University of Maryland School of Medicine researchers at the 110th general meeting of the American Society for Microbiology in San Diego.

27 May 2010

Restanza shows greater efficacy against species of Plasmodium that cause malaria

Advanced Life Sciences Holdings, Inc., a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, oncology and respiratory diseases, today announced positive results from in vitro and in vivo studies assessing the efficacy of Restanza (cethromycin), its novel oral antibiotic, against the species of Plasmodium that cause malaria.

27 May 2010

Researchers examine association between use of antibiotics and outcomes among patients with COPD

Among patients hospitalized for acute exacerbations of chronic obstructive pulmonary disease, those who received antibiotics in the first 2 hospital days had improved outcomes, such as a lower likelihood of mechanical ventilation and fewer readmissions, compared to patients who received antibiotics later or not at all, according to a study in the May 26 issue of JAMA.

26 May 2010

Antibiotic News and Research

Further Reading

FDA grants Cepheid marketing clearance for Xpert SA Nasal Complete molecular test

Salix submits efficacy supplement for XIFAXAN NDA for Non-C IBS and IBS-related bloating

Acella Pharmaceuticals signs license agreement for marketing rights to generic broad-spectrum antibiotic

Researchers develop biosensors to monitor concentration of c-di-GMP within single living bacteria cells

Lovastatin protects animals against plague

Phase 1B clinical study with PMX-60056 meets safety and efficacy endpoints: PolyMedix

Oculus launches Microcyn Negative-Pressure Wound Therapy Solution

Santarus commences enrollment in rifamycin SV MMX Phase III clinical program for travelers' diarrhea

Azithromycin as effective as penicillin for early-stage syphilis: Study

Tetraphase Pharmaceuticals raises $45M in Series C financing

AAPA recognizes role of PAs in transforming health care delivery with 2010 PAragon Awards

Helicobacter pylori's helical shape helps it colonize the stomach

Advanced Life Sciences expands partnership with U.S. Government to assess Restanza against STI's

Researchers see plectasin as promising lead compound for new antibiotics

CrystalGenomics to merge with BexPharm

Progenics presents preclinical data on novel monoclonal antibodies against toxins produced by C. difficile

National Science Foundation supports PolyMedix with $150,000 grant for development of antimicrobial sutures

Bacteria may play wider role in people predisposed to obesity: Researchers

Restanza shows greater efficacy against species of Plasmodium that cause malaria

Researchers examine association between use of antibiotics and outcomes among patients with COPD

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News